JP6361039B2 - 疾患に対する免疫反応を誘導するための併用療法 - Google Patents
疾患に対する免疫反応を誘導するための併用療法 Download PDFInfo
- Publication number
- JP6361039B2 JP6361039B2 JP2016506307A JP2016506307A JP6361039B2 JP 6361039 B2 JP6361039 B2 JP 6361039B2 JP 2016506307 A JP2016506307 A JP 2016506307A JP 2016506307 A JP2016506307 A JP 2016506307A JP 6361039 B2 JP6361039 B2 JP 6361039B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- cells
- cell
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361807998P | 2013-04-03 | 2013-04-03 | |
| US61/807,998 | 2013-04-03 | ||
| US13/966,450 US9315567B2 (en) | 2012-08-14 | 2013-08-14 | T-cell redirecting bispecific antibodies for treatment of disease |
| US13/966,450 | 2013-08-14 | ||
| PCT/US2013/075201 WO2014163684A1 (en) | 2013-04-03 | 2013-12-14 | Combination therapy for inducing immune response to disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018085760A Division JP2018135371A (ja) | 2013-04-03 | 2018-04-26 | 疾患に対する免疫反応を誘導するための併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016520548A JP2016520548A (ja) | 2016-07-14 |
| JP2016520548A5 JP2016520548A5 (cg-RX-API-DMAC10.html) | 2016-12-22 |
| JP6361039B2 true JP6361039B2 (ja) | 2018-07-25 |
Family
ID=51658778
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016506307A Active JP6361039B2 (ja) | 2013-04-03 | 2013-12-14 | 疾患に対する免疫反応を誘導するための併用療法 |
| JP2018085760A Pending JP2018135371A (ja) | 2013-04-03 | 2018-04-26 | 疾患に対する免疫反応を誘導するための併用療法 |
| JP2019038757A Expired - Fee Related JP6767029B2 (ja) | 2013-04-03 | 2019-03-04 | 疾患に対する免疫反応を誘導するための併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018085760A Pending JP2018135371A (ja) | 2013-04-03 | 2018-04-26 | 疾患に対する免疫反応を誘導するための併用療法 |
| JP2019038757A Expired - Fee Related JP6767029B2 (ja) | 2013-04-03 | 2019-03-04 | 疾患に対する免疫反応を誘導するための併用療法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2981281B1 (cg-RX-API-DMAC10.html) |
| JP (3) | JP6361039B2 (cg-RX-API-DMAC10.html) |
| CN (2) | CN105073128A (cg-RX-API-DMAC10.html) |
| CA (1) | CA2899577C (cg-RX-API-DMAC10.html) |
| WO (1) | WO2014163684A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| US10570202B2 (en) | 2014-02-04 | 2020-02-25 | Pfizer Inc. | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
| ES2978993T3 (es) * | 2014-02-21 | 2024-09-23 | Ibc Pharmaceuticals Inc | Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2 |
| ES2913205T3 (es) | 2014-05-13 | 2022-06-01 | Bioatla Inc | Proteínas biológicas activas condicionalmente |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| SG11201704056XA (en) * | 2014-11-20 | 2017-06-29 | Hoffmann La Roche | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11512289B2 (en) | 2015-02-18 | 2022-11-29 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| KR20170132171A (ko) | 2015-02-26 | 2017-12-01 | 메르크 파텐트 게엠베하 | 암 치료를 위한 pd1 / pdl1 저해제 |
| JP6803339B2 (ja) | 2015-04-21 | 2020-12-23 | エンリヴェックス セラピューティクス リミテッド | 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用 |
| ES2984656T3 (es) * | 2015-05-13 | 2024-10-30 | Ablynx Nv | Polipéptidos que reclutan linfocitos T en función de la reactividad a CD3 |
| US20180312561A1 (en) * | 2015-06-12 | 2018-11-01 | Immungene, Inc. | Focused interferon immunotherapy for treatment of cancer |
| AU2016274989A1 (en) * | 2015-06-12 | 2017-11-02 | Immunomedics, Inc. | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs |
| RU2766890C2 (ru) | 2015-06-16 | 2022-03-16 | Мерк Патент Гмбх | Комбинированные способы лечения антагонистами pd-l1 |
| CA2986066A1 (en) * | 2015-06-30 | 2017-01-05 | Boehringer Ingelheim International Gmbh | Multi-specific binding proteins |
| TWI746449B (zh) * | 2015-07-20 | 2021-11-21 | 美商Ai治療公司 | 使用阿吡莫德治療癌症之方法 |
| BR112018012352A2 (pt) | 2015-12-16 | 2018-12-11 | Merck Sharp & Dohme Corp. | anticorpos anti-lag3 e fragmentos de ligação ao antígeno |
| EP3400218A4 (en) | 2016-01-08 | 2019-09-18 | Euclises Pharmaceuticals, Inc. | COMBINATION OF A CHROME CONNECTION AND A SECOND ACTIVE SUBSTANCE |
| BR112018011029A2 (pt) | 2016-01-08 | 2018-11-21 | Hoffmann La Roche | métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits |
| JP6884155B2 (ja) | 2016-02-18 | 2021-06-09 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための併用免疫療法及びサイトカイン制御療法 |
| ES3056995T3 (en) * | 2016-04-13 | 2026-02-25 | Vivia Biotech Sl | Ex vivo bite-activated t cells |
| US20190282679A1 (en) * | 2016-04-18 | 2019-09-19 | Rima McLeod | Toxoplasma gondii vaccines and their use |
| CN109790581A (zh) * | 2016-04-27 | 2019-05-21 | 米拉迪克斯有限公司 | Kras-变体癌症患者的基于免疫的治疗 |
| RU2725292C2 (ru) * | 2016-04-27 | 2020-06-30 | Иммьюномедикс, Инк. | Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей |
| EP3450460B1 (en) * | 2016-04-29 | 2023-07-12 | Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
| US20190147976A1 (en) * | 2016-05-05 | 2019-05-16 | Nantomics, Llc | Checkpoint failure and methods therefor |
| CA3026563C (en) | 2016-06-10 | 2023-11-28 | Io Therapeutics, Inc. | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy |
| CN105943510A (zh) * | 2016-06-13 | 2016-09-21 | 佛山市腾瑞医药科技有限公司 | 一种艾代拉利司制剂及其应用 |
| US12653874B2 (en) | 2016-06-30 | 2026-06-16 | Immunitybio, Inc. | Nant cancer vaccine |
| KR20210010678A (ko) * | 2016-06-30 | 2021-01-27 | 난트 홀딩스 아이피, 엘엘씨 | 난트 암 백신 |
| US20190170752A1 (en) * | 2016-08-08 | 2019-06-06 | Beigene, Ltd. | Method for predicting efficacy of immune checkpoint inhibitors in cancer patients |
| EP3515951B1 (en) | 2016-09-23 | 2024-02-28 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
| US12188935B2 (en) | 2016-09-30 | 2025-01-07 | Centre National De La Recherche Scientifique | Method for the evaluation of antiretroviral therapy (ART) effectiveness in HIV-1 CD4+CD89+ cellular reservoirs |
| EP3519822B1 (fr) * | 2016-09-30 | 2021-05-12 | Centre National De La Recherche Scientifique | Marqueurs cellulaires |
| BR112019006504A2 (pt) | 2016-10-06 | 2019-06-25 | Pfizer Inc. | regime de dosagem de avelumabe para o tratamento de câncer |
| JP6948685B2 (ja) * | 2016-11-04 | 2021-10-13 | 国立大学法人金沢大学 | 抗癌作用増強剤及び癌治療支援方法 |
| EP3534935A1 (en) * | 2016-11-04 | 2019-09-11 | Vaximm AG | Wt1 targeting dna vaccine for combination therapy |
| US20200062836A1 (en) * | 2016-11-16 | 2020-02-27 | Eli Lilly And Company | THERAPY FOR METATASTIC COLORECTAL CANCER USING ANTI-VEGFR-2 and ANTI-VEGF-D ANTIBODIES |
| EP3576765B1 (en) | 2017-02-06 | 2025-07-16 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| JP2020508323A (ja) * | 2017-02-23 | 2020-03-19 | ラクテン メディカル インコーポレイテッド | 光免疫療法のための治療用組成物および関連する方法 |
| EP3601357A1 (en) * | 2017-03-29 | 2020-02-05 | Glycotope GmbH | Multispecific antibody constructs binding to muc1 and cd3 |
| KR20190136076A (ko) * | 2017-04-13 | 2019-12-09 | 에프. 호프만-라 로슈 아게 | 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제 |
| CA3069672A1 (en) | 2017-07-13 | 2019-01-17 | Io Therapeutics, Inc. | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy |
| CA3073953A1 (en) | 2017-08-31 | 2019-03-07 | Io Therapeutics, Inc. | Rar selective agonists in combination with immune modulators for cancer immunotherapy |
| JP7236385B2 (ja) * | 2017-09-26 | 2023-03-09 | 中外製薬株式会社 | 医薬組成物 |
| US20190184028A1 (en) * | 2017-12-14 | 2019-06-20 | Janssen Biotech, Inc. | Targeting with firbronectin type iii like domain molecules |
| CN109954131B (zh) * | 2017-12-14 | 2023-05-02 | 深圳市中科艾深医药有限公司 | 一种肿瘤坏死因子相关凋亡诱导配体拮抗剂作为脓毒血症治疗药物的应用 |
| JP7555270B2 (ja) * | 2018-02-13 | 2024-09-24 | プレシジョン バイオロジックス、インコーポレイテッド | Treg細胞を標的とするための方法及び組成物 |
| KR102373502B1 (ko) | 2018-05-14 | 2022-03-11 | 주식회사 금호에이치티 | 골수유래억제세포 관련 질환의 예방 및 치료 용도 |
| EP3569617A1 (en) * | 2018-05-18 | 2019-11-20 | Trion Research GmbH | Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases |
| US20220002398A1 (en) * | 2018-06-07 | 2022-01-06 | Oncoone Research & Development Gmbh | ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT |
| JP7541930B2 (ja) * | 2018-06-29 | 2024-08-29 | ジーオー セラピューティクス,インコーポレイテッド | 抗グリコmuc1抗体およびその使用 |
| CN113164445A (zh) * | 2018-08-02 | 2021-07-23 | 得克萨斯系统大学评议会 | Tlr1/2激动剂地普罗考姆的佐剂作用协同增效检查点抑制性抗体以消除疾病 |
| MX2021002302A (es) * | 2018-08-29 | 2021-04-28 | Chemocentryx Inc | Terapia de combinacion usando antagonistas de receptor de quimiocina c-c 4 (ccr4) y uno o mas inhibidores de punto de control. |
| AU2019354105A1 (en) * | 2018-10-04 | 2021-04-29 | Genmab Holding B.V. | Pharmaceutical compositions comprising bispecific anti-CD37 antibodies |
| CN113227121A (zh) * | 2018-10-05 | 2021-08-06 | Rnagene公司 | 通过特异性结合至靶细胞具有增强的多种免疫功能的嵌合抗原及其用途 |
| US12257286B2 (en) | 2018-10-31 | 2025-03-25 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12624086B2 (en) | 2018-10-31 | 2026-05-12 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
| JP7521163B2 (ja) | 2018-12-19 | 2024-07-24 | ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ | 抗ceacam6及びtim3抗体の医薬組み合わせ |
| CN110438081B (zh) * | 2018-12-27 | 2023-04-14 | 重庆医药高等专科学校附属第一医院 | 人套细胞淋巴瘤恶性克隆细胞株及其建立方法和应用 |
| WO2020152122A1 (en) * | 2019-01-21 | 2020-07-30 | Singapore Health Services Pte. Ltd. | Treatment of hepatotoxicity |
| KR20220012313A (ko) | 2019-05-23 | 2022-02-03 | 벨로스바이오 인코포레이티드 | 항-ror1/항-cd3 이중특이적 결합 분자 |
| KR20210021861A (ko) * | 2019-08-19 | 2021-03-02 | (주)제노팜 | 사람 표피성장인자수용체 2 양성 암을 치료하기 위한 인터페론-베타 변이체 면역사이토카인의 용도 및 환자 선별 방법 |
| EP4061487A4 (en) * | 2019-11-19 | 2023-12-20 | Rootpath Genomics, Inc. | COMPOSITIONS AND METHODS FOR IDENTIFYING T CELL RECEPTOR |
| CA3163358A1 (en) | 2019-12-03 | 2021-06-10 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| CA3172949A1 (en) * | 2020-03-27 | 2021-09-30 | Robert Z. Orlowski | Monoclonal antibodies targeting hsp70 and therapeutic uses thereof |
| US20230241237A1 (en) * | 2020-04-16 | 2023-08-03 | Emory University | Immune Cell Redirecting Compositions and Therapeutic Uses Thereof |
| CN111705013B (zh) * | 2020-06-02 | 2021-12-07 | 华中农业大学 | 一种牛支原体Mbov_0570基因突变株及其应用 |
| CA3182769A1 (en) * | 2020-06-15 | 2021-12-23 | Andrew P. Mazar | Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (upar) for treatment of severe covid-19 disease |
| CN111850002B (zh) * | 2020-06-22 | 2022-04-19 | 华中农业大学 | 牛支原体分泌蛋白MbovP570的应用 |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| US20240092931A1 (en) * | 2020-08-24 | 2024-03-21 | Janux Therapeutics, Inc. | Antibodies targeting trop2 and cd3 and uses thereof |
| JP2023539525A (ja) * | 2020-09-02 | 2023-09-14 | ジェンマブ エー/エス | 抗体療法 |
| EP4247412A4 (en) * | 2020-11-18 | 2024-10-23 | University of Florida Research Foundation, Inc. | Materials and methods for sensitizing tumors to immune response |
| JP2022157223A (ja) * | 2021-03-31 | 2022-10-14 | 国立大学法人神戸大学 | 抗ガン剤効果増強剤 |
| JP7900421B2 (ja) | 2021-06-11 | 2026-08-04 | ギリアード サイエンシーズ, インコーポレイテッド | Mcl-1阻害剤と抗がん剤との組み合わせ |
| TWI861509B (zh) | 2021-06-11 | 2024-11-11 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗體藥物接合物之組合 |
| CN115671253B (zh) * | 2021-07-30 | 2024-02-27 | 河北菲尼斯生物技术有限公司 | Se-dr亲和肽在制备治疗风湿疾病的药物中的用途 |
| CN118541392A (zh) * | 2021-09-28 | 2024-08-23 | 准星生物医药有限公司 | 多种形式的分子复合物 |
| EP4423078A1 (en) | 2021-10-28 | 2024-09-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| CN118488948A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN114209652B (zh) * | 2021-12-29 | 2022-08-09 | 中山大学附属第一医院 | 一种微环境nk细胞免疫调控递送系统及其制备方法和应用 |
| CN114300089B (zh) * | 2022-01-04 | 2024-09-03 | 哈尔滨医科大学 | 一种中晚期结直肠癌治疗方案决策算法 |
| CA3248911A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS |
| IL314993A (en) | 2022-02-23 | 2024-10-01 | Xencor Inc | Anti-cd28 x anti-psma antibodies |
| EP4482865A1 (en) * | 2022-02-24 | 2025-01-01 | Xencor, Inc. | Anti-cd28 x anti-trop2 antibodies |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| JP2025512426A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ, インコーポレイテッド | 腫瘍抗原発現がんを治療するための併用療法 |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| EP4511127A1 (en) | 2022-04-21 | 2025-02-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024012513A1 (en) * | 2022-07-13 | 2024-01-18 | Hansoh Bio Llc | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
| WO2024097812A1 (en) | 2022-11-04 | 2024-05-10 | Gilead Sciences, Inc. | Therapy for treating bladder cancer |
| CN115975026B (zh) * | 2022-11-15 | 2024-06-25 | 青海大学 | 一种抗多房棘球蚴原头节的纳米抗体、重组菌及其应用 |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| JP2026522894A (ja) | 2023-06-30 | 2026-07-09 | ギリアード サイエンシーズ, インコーポレイテッド | Kras調節化合物 |
| CN121568935A (zh) | 2023-07-26 | 2026-02-24 | 吉利德科学公司 | Parp7抑制剂 |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025027090A1 (en) * | 2023-07-31 | 2025-02-06 | Danmarks Tekniske Universitet | Inhibitors of cell envelope proteinases from lactic acid bacteria |
| EP4774280A1 (en) | 2023-09-08 | 2026-07-15 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN116874606B (zh) * | 2023-09-08 | 2023-11-24 | 益科思特(北京)医药科技发展有限公司 | 一种靶向trop2和cd3的双特异性抗体及其制备方法与应用 |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025184896A1 (zh) * | 2024-03-08 | 2025-09-12 | 四川大学华西医院 | 增强免疫检查点抑制剂抗肿瘤疗效的方法和药物及其应用 |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20260130893A1 (en) | 2024-10-21 | 2026-05-14 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026136515A1 (en) | 2024-12-19 | 2026-06-25 | Gilead Sciences, Inc. | Parp7 inhibitors |
| CN120518757B (zh) * | 2025-07-23 | 2025-09-23 | 中国人民解放军军事科学院军事医学研究院 | 一种聚乙二醇化多价抗西尼罗病毒单链抗体 |
| CN121293363B (zh) * | 2025-12-09 | 2026-04-21 | 上海玄言生物科技有限公司 | 一种靶向cd14和cd3的双功能t细胞衔接器及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550143B2 (en) * | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US20110020273A1 (en) * | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| US8481041B2 (en) * | 2005-04-06 | 2013-07-09 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy |
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| AU2006262231B2 (en) * | 2005-06-20 | 2013-01-24 | Psma Development Company, Llc | PSMA antibody-drug conjugates |
| NZ568016A (en) * | 2005-12-07 | 2011-12-22 | Medarex Inc | CTLA-4 antibody dosage escalation regimens |
| EP2225275A4 (en) * | 2007-11-28 | 2013-04-03 | Medimmune Llc | PROTEIN FORMULATION |
| WO2010017500A2 (en) * | 2008-08-08 | 2010-02-11 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
| CA2772572A1 (en) * | 2009-08-31 | 2011-03-03 | Ibc Pharmaceuticals, Inc. | Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof |
| US9249217B2 (en) * | 2010-12-03 | 2016-02-02 | Secretary, DHHS | Bispecific EGFRvIII x CD3 antibody engaging molecules |
| WO2012143524A2 (en) * | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| BR112014002353B1 (pt) * | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| AU2013302696B9 (en) * | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
-
2013
- 2013-12-14 CN CN201380075311.8A patent/CN105073128A/zh active Pending
- 2013-12-14 WO PCT/US2013/075201 patent/WO2014163684A1/en not_active Ceased
- 2013-12-14 JP JP2016506307A patent/JP6361039B2/ja active Active
- 2013-12-14 EP EP13880736.7A patent/EP2981281B1/en active Active
- 2013-12-14 CN CN201710604357.4A patent/CN107252485A/zh active Pending
- 2013-12-14 CA CA2899577A patent/CA2899577C/en active Active
-
2018
- 2018-04-26 JP JP2018085760A patent/JP2018135371A/ja active Pending
-
2019
- 2019-03-04 JP JP2019038757A patent/JP6767029B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP6767029B2 (ja) | 2020-10-14 |
| JP2016520548A (ja) | 2016-07-14 |
| JP2018135371A (ja) | 2018-08-30 |
| JP2019108373A (ja) | 2019-07-04 |
| EP2981281A1 (en) | 2016-02-10 |
| CN107252485A (zh) | 2017-10-17 |
| EP2981281A4 (en) | 2017-04-26 |
| CA2899577A1 (en) | 2014-10-09 |
| CA2899577C (en) | 2023-10-17 |
| EP2981281B1 (en) | 2020-07-15 |
| CN105073128A (zh) | 2015-11-18 |
| WO2014163684A1 (en) | 2014-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6767029B2 (ja) | 疾患に対する免疫反応を誘導するための併用療法 | |
| US10111954B2 (en) | Combination therapy for inducing immune response to disease | |
| US10245321B2 (en) | Combination therapy for inducing immune response to disease | |
| JP6759508B2 (ja) | Trop−2発現細胞に対する免疫応答を誘発することによる疾患治療 | |
| US10131712B2 (en) | Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors | |
| US10662252B2 (en) | Disease therapy by inducing immune response to Trop-2 expressing cells | |
| AU2018236844B2 (en) | T-cell redirecting bispecific antibodies for treatment of disease | |
| WO2017210058A1 (en) | Combination therapy with t-cell redirecting bispecific antibodies and checkpoint inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161101 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161101 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171031 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180327 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180426 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180510 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180529 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180531 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6361039 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |